Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions
Thoracic Cancer Journal · 03.01.2025 · 1 (2)
DOI: 10.82582/thorac.51 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer Journal, erschienen am 03.01.2025. Verfasst von Silva und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, representing the majority of cancer-related deaths worldwide. Recent advances have shifted treatment paradigms from conventional chemotherapy to precision oncology approaches, particularly molecularly targeted therapies. This review focuses on pivotal molecular drivers such as EGFR, ALK, KRAS, MET, HER2, and RET, synthesizing content from recent studies and editorial perspectives. Targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have redefined patient care by improving progression-free and overall survival. However, resistance mechanisms remain a challenge, necessitating innovative strategies and combination approaches. This article integrates perspectives to provide a comprehensive overview of NSCLC target therapeutic progress and future directions.
Schlagwörter
Zitieren
APA
Silva, & Sonia (2025). Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions. Thoracic Cancer Journal, 1(2). https://doi.org/10.82582/thorac.51
Vancouver
Silva, Sonia. Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions. Thoracic Cancer Journal. 2025;1(2). doi:10.82582/thorac.51
BibTeX
@article{Silva2025,
author = {Silva and Sonia},
title = {Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions},
journal = {Thoracic Cancer Journal},
year = {2025},
volume = {1},
number = {2},
doi = {10.82582/thorac.51}
}
EUVIMED